$PHIO
Phio Pharmaceuticals Corp Stock $phio

$phio Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000168316823001678 Filed on March 22, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.468M	$1.116M	$4.450M
YoY Change	39.28%	-32.57%	-3.78%
% of Gross Profit
Research & Development	$2.134M	$1.614M	$7.012M
YoY Change	34.55%	-10.08%	-21.09%
% of Gross Profit
Depreciation & Amortization	$16.00K	$15.00K	$71.00K
YoY Change	-27.27%	-25.0%	-5.33%
% of Gross Profit
Operating Expenses	$3.602M	$2.730M	$11.46M
YoY Change	36.44%	-20.87%	-15.17%
Operating Profit	-$3.602M		-$11.46M
YoY Change	36.44%		-15.17%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$0.00	-$1.000K	-$18.00K
YoY Change	-100.0%		-108.04%
Pretax Income	-$3.602M	-$2.731M	-$11.48M
YoY Change	36.34%	-20.86%	-13.6%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$3.602M	-$2.731M	-$11.48M
YoY Change	36.34%	-20.86%	-13.6%
Net Earnings / Revenue
Basic Earnings Per Share	-$3.15		-$10.10
Diluted Earnings Per Share	-$3.15	-$2.40	-$10.10
COMMON SHARES
Basic Shares Outstanding	1.151M shares	13.67M shares	1.137M shares
Diluted Shares Outstanding	1.142M shares		1.137M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.035M	$11.78M	$11.78M
YoY Change	-55.84%	-51.03%	-51.03%
Cash & Equivalents	$9.085M	$11.83M	$11.78M
Short-Term Investments
Other Short-Term Assets	$369.0K	$665.0K	$665.0K
YoY Change	-69.45%	-0.75%	-0.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$9.404M	$12.45M	$12.45M
YoY Change	-56.6%	-49.67%	-49.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$167.0K	$183.0K	$344.0K
YoY Change	-64.32%	37.59%	-17.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.000K	$24.00K	$24.00K
YoY Change	-77.78%	-11.11%	-11.11%
Total Long-Term Assets	$303.0K	$368.0K	$368.0K
YoY Change	-38.79%	-16.93%	-16.93%
TOTAL ASSETS
Total Short-Term Assets	$9.404M	$12.45M	$12.45M
Total Long-Term Assets	$303.0K	$368.0K	$368.0K
Total Assets	$9.707M	$12.81M	$12.81M
YoY Change	-56.2%	-49.09%	-49.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$902.0K	$779.0K	$779.0K
YoY Change	174.16%	175.27%	175.27%
Accrued Expenses	$1.356M	$1.025M	$1.160M
YoY Change	-39.57%	-61.47%	-58.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.396M	$1.939M	$1.939M
YoY Change	-6.88%	-36.8%	-36.8%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$34.89K	$34.89K
YoY Change	-100.0%	-79.48%	-79.48%
Total Long-Term Liabilities	$0.00	$34.89K	$34.89K
YoY Change	-100.0%	-79.48%	-79.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.396M	$1.939M	$1.939M
Total Long-Term Liabilities	$0.00	$34.89K	$34.89K
Total Liabilities	$2.396M	$1.974M	$1.974M
YoY Change	-11.62%	-39.04%	-39.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$132.0M	-$128.4M
YoY Change		9.82%
Common Stock	$0.00	$0.00
YoY Change		-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.311M	$10.84M	$10.84M
YoY Change
Total Liabilities & Shareholders Equity	$9.707M	$12.81M	$12.81M
YoY Change	-56.2%	-49.09%	-49.09%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$3.602M	-$2.731M	-$11.48M
YoY Change	36.34%	-20.86%	-13.6%
Depreciation, Depletion And Amortization	$16.00K	$15.00K	$71.00K
YoY Change	-27.27%	-25.0%	-5.33%
Cash From Operating Activities	-$2.708M	-$2.705M	-$12.13M
YoY Change	-21.94%	9.47%	2.29%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$121.0K
YoY Change	-100.0%		-337.25%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$121.0K
YoY Change	-100.0%		137.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$38.00K	2.000K	-$26.00K
YoY Change	52.0%	-300.0%	-100.12%
NET CHANGE
Cash From Operating Activities	-$2.708M	-2.705M	-$12.13M
Cash From Investing Activities	$0.00	0.000	-$121.0K
Cash From Financing Activities	-$38.00K	2.000K	-$26.00K
Net Change In Cash	-$2.746M	-2.703M	-$12.28M
YoY Change	-23.68%	9.34%	-225.1%
FREE CASH FLOW
Cash From Operating Activities	-$2.708M	-$2.705M	-$12.13M
Capital Expenditures	$0.00	$0.00	$121.0K
Free Cash Flow	-$2.708M	-$2.705M	-$12.25M
YoY Change	-19.52%	9.47%	3.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001533040
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2022	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36304
CY2022	dei	Entity Registrant Name EntityRegistrantName	PHIO PHARMACEUTICALS CORP.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-3215903
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	257 Simarano Drive
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 101
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Marlborough
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01752
CY2022	dei	City Area Code CityAreaCode	508
CY2022	dei	Local Phone Number LocalPhoneNumber	767-3861
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value, $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	PHIO
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	9500000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1150582	shares
CY2022	dei	Auditor Firm AuditorFirmId	243
CY2022	dei	Auditor Name AuditorName	BDO USA, LLP
CY2022	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2022Q4	us-gaap	Cash Cash	11781000	usd
CY2021Q4	us-gaap	Cash Cash	24057000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	50000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	50000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	615000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	620000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	12446000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	24727000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	161000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	283000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	183000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	133000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	27000	usd
CY2022Q4	us-gaap	Assets Assets	12814000	usd
CY2021Q4	us-gaap	Assets Assets	25170000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	779000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	283000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1025000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2660000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	135000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	125000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1939000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3068000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	35000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	170000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1974000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	3238000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1139024	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1139024	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1127917	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1127917	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	139218000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	138832000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-128380000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116900000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10838000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	21932000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12814000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25170000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7012000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8886000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4450000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4625000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	11462000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	13511000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-11462000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-13511000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	224000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11480000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13287000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11480000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13287000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.10
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.43
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-10.10
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.43
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1136566	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1069234	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1136566	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1069234	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	13017000	usd
CY2021	phio	Issuance Of Common Stock Prefunded Warrants And Warrants In Connection With Private Placement Net Of Offering Costs IssuanceOfCommonStockPrefundedWarrantsAndWarrantsInConnectionWithPrivatePlacementNetOfOfferingCosts	12669000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6908000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2146000	usd
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	480000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13287000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	21932000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	28000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	414000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11480000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10838000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11480000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13287000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	71000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	75000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	122000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	117000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	414000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	480000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	233000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-241000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	496000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-445000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1635000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1310000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-125000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-116000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12129000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11858000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	121000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	51000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-121000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-51000	usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	0	usd
CY2021	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	19577000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2146000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	28000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1000	usd
CY2022	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	2000	usd
CY2021	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-26000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21722000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-12276000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9813000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24107000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14294000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11831000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24107000	usd
CY2022Q4	us-gaap	Cash Cash	11781000	usd
CY2021Q4	us-gaap	Cash Cash	24057000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	50000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	50000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11831000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24107000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_84B_eus-gaap--NatureOfOperations_zqZOtW3TDga9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_864_z3qzzUGtC505">Nature of Operations</span> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Phio Pharmaceuticals Corp. (“<b>Phio</b>,” “<b>we</b>,” “<b>our</b>” or the “<b>Company</b>”) is a clinical stage biotechnology company whose proprietary INTASYL™ self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. We are committed to discovering and developing innovative cancer treatments for patients by creating new pathways toward a cancer-free future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company continues to respond to and monitor the ongoing coronavirus pandemic. The Company believes that the coronavirus pandemic has not had a significant impact on its financial condition and results of operations, however, the extent to which the coronavirus pandemic may materially impact our financial results and operations will depend on a number of factors, including the availability of supplies and services we rely on, the ability to enroll subjects in our clinical trials, the emergence of variant strains of the coronavirus, the development, availability, and public acceptance of effective treatments and vaccines, and the duration of the coronavirus pandemic, which remain difficult to predict and are highly uncertain.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zyB3Rskx9Xqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_865_zJFpgU2X2Isg">Concentrations of Credit Risk</span> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains cash balances in several accounts with a financial institution that management believes is creditworthy, which at times are in excess of federally insured limits. These accounts are insured by the Federal Deposit Insurance Corporation for up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zAIbJZqZ7wH4">250,000</span> per institution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-12 reverse stock split
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zVOijOKDTId7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_861_z5PgkMqSU5mk">Uses of Estimates in Preparation of Financial Statements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas subject to significant estimates and judgement include, among others, those related to the fair value of equity awards, accruals for research and development expenses, useful lives of property and equipment, income taxes, and the valuation allowance on our deferred tax assets. On an ongoing basis we evaluate our estimates and base our estimates on historical experience and other relevant assumptions that we believe are reasonable under the circumstances. Actual results could differ materially from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p>
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	116000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	108000	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1077000	usd
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1035000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	119000	usd
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	49000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	46000	usd
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	46000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1358000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1238000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1175000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1105000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	183000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	133000	usd
CY2022	us-gaap	Depreciation Depreciation	71000	usd
CY2021	us-gaap	Depreciation Depreciation	75000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	408000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	572000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	97000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	102000	usd
CY2022Q4	phio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	501000	usd
CY2021Q4	phio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	1986000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	19000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1025000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2660000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	161000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	283000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	135000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	125000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	35000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	170000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	170000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	295000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0470	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0470	pure
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	132000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	132000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	135000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	132000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	140000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	35000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	175000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	170000	usd
CY2022	phio	Milestone Payments MilestonePayments	0	usd
CY2021	phio	Milestone Payments MilestonePayments	0	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	100000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	100000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	100000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	100000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	100000	usd
CY2022Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	200000	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	700000	usd
CY2022	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	0	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022	phio	Warrants Exercised Shares WarrantsExercisedShares	0	shares
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2146000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	414000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	480000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1733000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3016000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-553000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1329000	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-2286000	usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-4345000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2286000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4345000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.074	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.085	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.008	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.032	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.043	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.308	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.340	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11808000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10150000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1227000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	946000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	435000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1363000	usd
CY2022Q4	phio	Deferred Tax Asset Research And Development Cost DeferredTaxAssetResearchAndDevelopmentCost	1662000	usd
CY2021Q4	phio	Deferred Tax Asset Research And Development Cost DeferredTaxAssetResearchAndDevelopmentCost	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1680000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2018000	usd
CY2022Q4	phio	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	46000	usd
CY2021Q4	phio	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	79000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	120000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	169000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16978000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14725000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	43000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	76000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	43000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	76000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16935000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14649000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	phio	Deferred Tax Asset Research And Development Cost DeferredTaxAssetResearchAndDevelopmentCost	1662000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	592870	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	576201	shares

Files In Submission

Name	View Source	Status
0001683168-23-001678-index-headers.html	Edgar Link	pending
0001683168-23-001678-index.html	Edgar Link	pending
0001683168-23-001678.txt	Edgar Link	pending
0001683168-23-001678-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
phio-20221231.xsd	Edgar Link	pending
phio_ex1002.htm	Edgar Link	pending
phio_ex1011.htm	Edgar Link	pending
phio_ex2301.htm	Edgar Link	pending
phio_ex3101.htm	Edgar Link	pending
phio_ex3201.htm	Edgar Link	pending
phio_i10k-123122.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
phio-20221231_pre.xml	Edgar Link	unprocessable
phio-20221231_cal.xml	Edgar Link	unprocessable
phio-20221231_def.xml	Edgar Link	unprocessable
phio_i10k-123122_htm.xml	Edgar Link	completed
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
phio-20221231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PHIO
Phio Pharmaceuticals Corp Stock $phio

2023 Q1 Form 10-K Financial Statement

#000168316823001678 Filed on March 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHIO Phio Pharmaceuticals Corp Stock $phio

2023 Q1 Form 10-K Financial Statement

#000168316823001678 Filed on March 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHIO
Phio Pharmaceuticals Corp Stock $phio